3 Results for "

the AV shunt model

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "the AV shunt model" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-125856
CAS No.: 1802425-99-5
Purity:  99.93%
Synonyms: BMS-986177; JNJ-70033093
Target:  

Factor Xa

Research Areas:  

Cardiovascular Disease

Milvexian is an orally bioavailable, small-molecule, reversible, direct antagonists of factor Xia, with the Ki of 0.11, 0.38, 0.64, 490, 350 nM for human, rabbit, dog, rat, mouse, respectively. Milvexian shows anti-thrombosis activity in vitro and in vivo, and can be used for thrombus study .
loading...
    loading...
Cat. No.: HY-175735
CAS No.: 2563884-39-7
Target:  

Factor XI

Research Areas:  

Cardiovascular Disease

Factor XI-IN-2 is a Factor XI activation inhibitor with an IC50 of 20 nM. Factor XI-IN-2 does not directly inhibit the enzymatic activity of FXIa, but specifically binds to the FXI enzyme precursor and allosterically inhibits the process by which it is activated by FXIIa. Factor XI-IN-2 inhibits thrombosis in the rabbit arteriovenous (AV) shunt thrombosis model. Factor XI-IN-2 can be used for the study of antithrombus .
loading...
    loading...
Cat. No.: HY-125856A
CAS No.: 1802426-00-1
Synonyms: BMS-986177 TFA; JNJ-70033093 TFA
Target:  

Factor Xa

Research Areas:  

Cardiovascular Disease

Milvexian TFA (BMS-986177 TFA) is a factor XIa inhibitor with biological activity to prevent venous thromboembolism. Milvexian TFA was effective in reducing the occurrence of venous thromboembolism in patients undergoing knee replacement surgery. Milvexian TFA has good selectivity and shows significant inhibitory effects on plasma kallikrein and trypsin. Milvexian TFA has a bioavailability of 32%, which means it has a high absorption rate in the body. Milvexian TFA showed a relatively low risk of bleeding in clinical trials .
loading...
    loading...